7,667 research outputs found
Where is the pseudoscalar glueball ?
The pseudoscalar mesons with the masses higher than 1 GeV are assumed to
belong to the meson decuplet including the glueball as the basis state
supplementing the standard nonet of light states
. The decuplet is investigated by means of an algebraic approach based
on hypothesis of vanishing the exotic commutators of "charges" and
their time derivatives. These commutators result in a system of equations
determining contents of the isoscalar octet state in the physical isoscalar
mesons as well as the mass formula including all masses of the decuplet:
, K(1460), , and . The physical
isoscalar mesons , are expressed as superpositions of the "ideal"
states ( and ) and the glueball with the mixing
coefficient matrix following from the exotic commutator restrictions. Among
four one-parameter families of the calculated mixing matrix (numerous solutions
result from bad quality of data on the and K(1460) masses) there is
one family attributing the glueball-dominant composition to the
meson. Similarity between the pseudoscalar and scalar decuplets, analogy
between the whole spectra of the and mesons and affinity of
the glueball with excited states are also noticed.Comment: 18 pp., 2. figs., 2 tabs.; Published version. One of the authors
withdraws his nam
Beyond homozygosity mapping: family-control analysis based on Hamming distance for prioritizing variants in exome sequencing
A major challenge in current exome sequencing in autosomal recessive (AR) families is the lack of an effective method to prioritize single-nucleotide variants (SNVs). AR families are generally too small for linkage analysis, and length of homozygous regions is unreliable for identification of causative variants. Various common filtering steps usually result in a list of candidate variants that cannot be narrowed down further or ranked. To prioritize shortlisted SNVs we consider each homozygous candidate variant together with a set of SNVs flanking it. We compare the resulting array of genotypes between an affected family member and a number of control individuals and argue that, in a family, differences between family member and controls should be larger for a pathogenic variant and SNVs flanking it than for a random variant. We assess differences between arrays in two individuals by the Hamming distance and develop a suitable test statistic, which is expected to be large for a causative variant and flanking SNVs. We prioritize candidate variants based on this statistic and applied our approach to six patients with known pathogenic variants and found these to be in the top 2 to 10 percentiles of ranks
Raising Bi-O bands above the Fermi energy level of hole-doped BiSrCaCuO and other cuprate superconductors
The Fermi surface (FS) of BiSrCaCuO
(Bi2212) predicted by band theory displays Bi-related pockets around the
point, which have never been observed experimentally. We show that
when the effects of hole doping either by substituting Pb for Bi or by adding
excess O in Bi2212 are included, the Bi-O bands are lifted above the Fermi
energy () and the resulting first-principles FS is in remarkable accord
with measurements. With decreasing hole-doping the Bi-O bands drop below
and the system self-dopes below a critical hole concentration. Computations on
other Bi- as well as Tl- and Hg-based compounds indicate that lifting of the
cation-derived band with hole doping is a general property of the electronic
structures of the cuprates.Comment: 4 pages, 4 figures; PRL (2006, in press
Pulmonary arterial hypertension: a current review of pharmacological management
Pulmonary hypertension (PHTN) is a rare and devastating disease characterized by progressive increases in pulmonary arterial pressure and pulmonary vascular resistance, which eventually leads to right ventricular failure and death. At present there is no cure for pulmonary arterial hypertension (PAH); however over the past decade targeted pharmaceutical options have become available for the treatment of PAH. Prior to evaluation for therapeutic options a definitive diagnosis of pulmonary arterial hypertension must be made via comprehensive physical exam and definitive diagnostic testing. Screening test of choice remains echocardiography and gold standard for definitive diagnosis is right heart catheterization. Once the establishment of a diagnosis of PAH is made therapeutic options may be a possibility based on a diagnostic algorithm and disease severity of the PAH patient. There are different classes of medications available with different mechanisms of actions which net a vasodilatory effect and improve exercise tolerance, quality of life as well and survival
- …